Syra Health Corp. Class A (SYRA) AI Stock Analysis

• Market Cap: $1.19M
• Dividend Yield: N/A
• Average Volume (3M): 9.76K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.36
• Revenue Growth: -3.14%
• EPS Growth: 81.98%
• Country: US
• Employees: 57
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): -0.02
• Shares Outstanding: 11,339,169
• 10 Day Avg. Volume: 11,249
• 30 Day Avg. Volume: 9,759
• PEG Ratio: 0.06
• Price to Book (P/B): 1.04
• Price to Sales (P/S): 0.37
• P/FCF Ratio: -1.02
• Enterprise Value/Market Cap: -0.75
• Enterprise Value/Revenue: -0.12
• Enterprise Value/Gross Profit: -0.38
• Enterprise Value/Ebitda: 0.73
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $0.11 ▲(21.11% Upside)

The overall stock score is primarily influenced by the company's strong revenue growth and the positive strategic move of appointing a new CEO. However, ongoing profitability challenges, negative cash flows, and a negative P/E ratio weigh heavily on the score. The technical analysis suggests short-term bullish momentum, but overbought conditions could lead to a pullback.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for Syra Health's digital health platforms and services, suggesting effective market penetration and customer acquisition strategies.

New CEO Appointment

The appointment of a new CEO with relevant industry experience can enhance strategic execution, potentially driving market expansion and operational improvements.

Low Leverage

Low leverage provides financial flexibility and reduces risk, allowing Syra Health to invest in growth opportunities without significant debt burden.

Negative Factors

Profitability Challenges

Ongoing profitability challenges highlight operational inefficiencies, which could hinder long-term financial sustainability and require strategic adjustments.

Negative Cash Flow

Negative cash flow indicates difficulties in generating cash from operations, potentially limiting Syra Health's ability to fund growth initiatives and manage financial obligations.

Historical Negative Equity

Historical negative equity suggests past financial instability, which may affect investor confidence and the company's ability to secure favorable financing terms.

Syra Health Corp. Class A Business Overview & Revenue Model

Company Description

Syra Health Corp. Class A (SYRA) is a healthcare-focused company that specializes in providing innovative solutions and services to improve patient care and streamline healthcare operations. Operating within the healthcare technology sector, Syra Health develops and integrates advanced digital health platforms, telemedicine services, and data analytics tools that empower healthcare providers and enhance patient engagement. The company's core offerings aim to increase accessibility, reduce costs, and improve health outcomes across various healthcare settings.

How the Company Makes Money

Syra Health Corp. generates revenue primarily through its subscription-based model for its digital health platforms, where healthcare providers pay a recurring fee for access to its technology and services. Additionally, the company earns income from transaction fees related to telemedicine consultations and data analytics services. Strategic partnerships with healthcare organizations and technology firms further enhance its revenue streams by enabling joint offerings and expanding market reach. The company's focus on improving operational efficiency for healthcare providers translates into cost savings, making its solutions attractive, which in turn drives customer acquisition and retention.

Syra Health Corp. Class A Financial Statement Overview

Summary

Syra Health Corp. shows strong revenue growth but struggles with profitability and cash flows. The balance sheet is moderately healthy with low leverage, yet historical negative equity poses a risk. The company needs to address operational inefficiencies and improve cash generation to achieve sustainable financial health.

Income Statement

The company has shown a revenue growth rate of 44.7% from 2023 to 2024, indicating strong top-line growth. However, the net profit margin is negative at -47.1% in 2024, showing ongoing profitability challenges. The gross profit margin improved slightly to 20.7%, but the EBIT and EBITDA margins remain negative, reflecting operational inefficiencies.

Balance Sheet

The debt-to-equity ratio is relatively low at 0.16, indicating conservative leverage. However, the return on equity is negative due to net losses. The equity ratio is 78.3%, suggesting a strong capital structure. Despite these strengths, the negative equity in previous years highlights potential financial instability.

Cash Flow

The free cash flow is negative and deteriorated by 6.1% from 2023 to 2024, indicating cash flow challenges. The operating cash flow to net income ratio is not favorable as both are negative, indicating inefficiencies in converting earnings into cash flows.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.50M	7.98M	5.52M	5.62M	1.41M	0.00
Gross Profit	2.35M	1.65M	1.41M	1.06M	430.35K	0.00
EBITDA	-1.23M	-3.68M	-2.84M	-2.07M	-3.07K	-4.27K
Net Income	-1.27M	-3.76M	-2.94M	-2.12M	-3.28K	-4.27K
Balance Sheet
Total Assets	3.26M	3.68M	4.92M	2.32M	536.89K	3.00K
Cash, Cash Equivalents and Short-Term Investments	1.98M	2.40M	3.28M	3.34K	100.01K	3.00K
Total Debt	232.35K	452.08K	248.10K	934.84K	342.86K	3.00K
Total Liabilities	1.05M	800.76K	910.07K	1.61M	544.04K	7.17K
Stockholders Equity	2.21M	2.88M	4.01M	710.10K	-7.15K	-4.17K
Cash Flow
Free Cash Flow	-231.03K	-2.94M	-2.77M	-2.37M	-94.49K	0.00
Operating Cash Flow	-231.03K	-2.93M	-2.76M	-2.24M	-88.20K	0.00
Investing Cash Flow	0.00	-11.11K	-15.25K	-121.26K	-6.29K	0.00
Financing Cash Flow	-372.49K	2.06M	6.05M	2.27M	191.50K	36.00K

Syra Health Corp. Class A Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.09
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SYRA, the sentiment is Positive. The current price of 0.09 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.08, and below the 200-day MA of 0.11, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 60.11 is Neutral, neither overbought nor oversold. The STOCH value of 65.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SYRA.

Syra Health Corp. Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SYRA	52 Neutral	$1.19M	-0.86	-45.71%	―	-3.14%	81.98%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AMS	51 Neutral	$14.00M	-6.29	-8.75%	―	17.84%	-156.13%
MODVQ	45 Neutral	$143.54K	―	―	―	-0.70%	-2.38%
CCEL	44 Neutral	$28.19M	-59.12	―	11.14%	-0.29%	94.56%
PIII	39 Underperform	$25.72M	-0.08	-257.39%	―	-2.15%	-6.72%
CCM	38 Underperform	$16.32M	-0.72	―	―	-22.38%	56.66%

Syra Health Corp. Class A Corporate Events

Syra Health Appoints Gregory Alexander as New CEO

On December 15, 2025, Syra Health’s board appointed healthcare executive and former U.S. Marine officer Gregory R. Alexander as chief executive officer, with his employment agreement and compensation package, including salary, bonus eligibility, equity grants and change-of-control severance protections, set to take effect on January 5, 2026. Announced publicly on December 18, 2025, the appointment brings in a seasoned growth-focused leader with extensive Medicare, Medicaid and population health experience, reflecting Syra Health’s bid to accelerate expansion in its core markets and signaling a strategic move to strengthen execution and value creation for customers, shareholders and the communities it serves.

Syra Health Corp. Amends Certificate of Incorporation

On November 14, 2025, Syra Health Corp.’s stockholders approved amendments to the company’s Certificate of Incorporation, which included the removal of an automatic conversion clause for Class B Common Stock upon the death of a stockholder and allowed transfers to immediate family members without conversion. The amendments were filed and became effective on November 18, 2025, potentially impacting the company’s stockholder structure and transferability of shares.

Syra Health Corp. Approves Key Amendments at Annual Meeting

On November 14, 2025, Syra Health Corp. held its Annual Meeting of Stockholders where several key decisions were made. All five nominees for the board of directors were elected to serve until the next annual meeting, and the appointment of M&K CPAs, PLLC as the independent accounting firm was ratified. Additionally, amendments to the company’s Certificate of Incorporation were approved, including the removal of automatic conversion of Class B stock upon a stockholder’s death and allowing transfers to family members without conversion.